Roche - Public Comps and Valuation Multiples

Roche Overview

About Roche

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Founded

1896

HQ

Employees

103.2K+

Website

roche.com

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
Medical Imaging & Diagnostics
BioTech

Financials

LTM Revenue $77.7B

LTM EBITDA $30.6B

EV

$286B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Roche Financials

As of August 2025, Roche reported last 12-month revenue of $77.7B and EBITDA of $30.6B.

In the same period, Roche generated $58.0B in LTM gross profit and $16.6B in net income.

See Roche valuation multiples based on analyst estimates

Roche P&L

In the most recent fiscal year, Roche reported revenue of $78.2B and EBITDA of $20.8B.

Roche expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Roche valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$77.7B	XXX	$78.2B	XXX	XXX	XXX
Gross Profit	$58.0B	XXX	$57.8B	XXX	XXX	XXX
Gross Margin	75%	XXX	74%	XXX	XXX	XXX
EBITDA	$30.6B	XXX	$20.8B	XXX	XXX	XXX
EBITDA Margin	39%	XXX	27%	XXX	XXX	XXX
EBIT	$27.1B	XXX	$16.8B	XXX	XXX	XXX
EBIT Margin	35%	XXX	22%	XXX	XXX	XXX
Net Profit	$16.6B	XXX	$10.4B	XXX	XXX	XXX
Net Margin	21%	XXX	13%	XXX	XXX	XXX
Net Debt	XXX	XXX	$34.7B	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Roche including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $77.7B. EBITDA for the last twelve months was $30.6B. In the most recent fiscal year, Roche achieved $78.2B in revenue and $20.8B in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$77.7B	Analyst estimates available to subscribers	$78.2B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$58.0B	Analyst estimates available to subscribers	$57.8B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	74.7% gross margin	Analyst estimates available to subscribers	73.9% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$30.6B	Analyst estimates available to subscribers	$20.8B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	39.4% EBITDA margin	Analyst estimates available to subscribers	26.6% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$27.1B	Analyst estimates available to subscribers	$16.8B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	34.9% EBIT margin	Analyst estimates available to subscribers	21.5% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$16.6B	Analyst estimates available to subscribers	$10.4B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	21.3% net profit margin	Analyst estimates available to subscribers	13.3% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$34.7B	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Roche

This financial data table provides comprehensive performance metrics for Roche, a company based in Switzerland. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Roche generated $77.7B in revenue over the last twelve months.
The company achieved $30.6B in EBITDA over the last twelve months.
Gross profit for the last twelve months was $58.0B.
Net income over the last twelve months reached $16.6B.

Fiscal Year Performance

In the most recent fiscal year, Roche reported $78.2B in total revenue.
Fiscal year EBITDA was $20.8B.
The company maintained a gross profit margin of 73.9% in the most recent fiscal year.
EBITDA margin for the fiscal year was 26.6%.
Net profit margin reached 13.3% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Roche. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Roche Stock Performance

Roche has current market cap of CHF 207B (or $260B), and EV of CHF 228B (or $286B).

Market Cap Evolution

Roche Stock Data

As of September 17, 2025, Roche's stock price is CHF 260 (or $326).

See Roche trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$286B	$260B	XXX	XXX	XXX	XXX	$24.46

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Roche Valuation Multiples

Roche's trades at 3.7x EV/Revenue multiple, and 13.7x EV/EBITDA.

See valuation multiples for Roche and 15K+ public comps

Roche Financial Valuation Multiples

As of September 17, 2025, Roche has market cap of $260B and EV of $286B.

Equity research analysts estimate Roche's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Roche has a P/E ratio of 15.7x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$260B	XXX	$260B	XXX	XXX	XXX
EV (current)	$286B	XXX	$286B	XXX	XXX	XXX
EV/Revenue	3.7x	XXX	3.7x	XXX	XXX	XXX
EV/EBITDA	9.3x	XXX	13.7x	XXX	XXX	XXX
EV/EBIT	10.6x	XXX	17.0x	XXX	XXX	XXX
EV/Gross Profit	4.9x	XXX	n/a	XXX	XXX	XXX
P/E	15.7x	XXX	25.1x	XXX	XXX	XXX
EV/FCF	15.3x	XXX	15.1x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Roche Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Roche Margins & Growth Rates

Roche's last 12 month revenue growth is 3%

Roche's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $0.4M for the same period.

Roche's rule of 40 is 34% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Roche's rule of X is 48% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Roche and other 15K+ public comps

Roche Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	3%	XXX	2%	XXX	XXX	XXX
EBITDA Margin	39%	XXX	27%	XXX	XXX	XXX
EBITDA Growth	4%	XXX	15%	XXX	XXX	XXX
Rule of 40	34%	XXX	30%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	48%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.8M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.4M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	25%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	52%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial